FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> BioCryst | peramivir

BioCryst outlines Phase III plans for peramivir

Tools
  • Email
  • Print
  • Comment
  • Contact Author
  • Reprint

Shares of BioCryst were buoyed by the news that the Birmingham, AL-based developer had responded to a request from the Department of Health and Human Services seeking information on how it could go about setting up an emergency stockpile of its experimental flu drug peramivir. And the company detailed plans for two new late-stage trials testing the intravenous antiviral drug on hospitalized patients.

In one trial researchers plan to test the efficacy of the drug used in combination with the current standard of care. That trial, which gets underway in November, will enroll 400 patients and BioCryst plans to finish in May, 2011. Another trial will further explore efficacy, safety and tolerability in patients who have the flu. That trial will wrap in June, 2011. Researchers should have no problem finding volunteers.

"The novel H1N1 2009 virus is already producing significant morbidity and mortality within North America, and I expect the burden on the healthcare system to increase in the coming weeks," said Michael Ison, an assistant professor at Northwestern University Feinberg School of Medicine and lead investigator for one of the studies. "This Phase III study will provide an important opportunity to evaluate peramivir in an area of unmet medical need for seriously ill patients in the hospital setting."

- see BioCryst's release
- here's the AP report

Related Articles:
BioCryst hypes international pacts for peramivir
BioCryst reports positive late-stage flu data for peramivir
BioCryst cuts staff in lead-up to trial results
BioCryst trial scuttled by short needles, fat arms

More stories about BioCryst   peramivir  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.